HC Wainwright began coverage on shares of Soligenix Inc (OTC:SNGX) in a research note published on Monday, July 17th, MarketBeat reports. The brokerage issued a buy rating and a $11.00 price objective on the stock.
Separately, Maxim Group reiterated a buy rating and issued a $4.00 target price on shares of Soligenix in a research note on Monday, June 19th.
Shares of Soligenix (OTC SNGX) traded down 9.13% during trading on Monday, reaching $2.04. The company had a trading volume of 128,611 shares. The firm has a 50-day moving average of $2.26 and a 200-day moving average of $2.45. The company’s market cap is $11.57 million. Soligenix has a 12-month low of $1.90 and a 12-month high of $8.50.
ILLEGAL ACTIVITY NOTICE: This piece of content was first published by Community Financial News and is owned by of Community Financial News. If you are accessing this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.com-unik.info/2017/08/11/hc-wainwright-initiates-coverage-on-soligenix-inc-sngx-updated-updated-updated.html.
Soligenix Company Profile
Soligenix, Inc is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two segments: BioTherapeutics and Vaccines/BioDefense. Its BioTherapeutics segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, and its innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer.
What are top analysts saying about Soligenix Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Soligenix Inc and related companies.